There were a few interesting/concerning tidbits in his email including:1. In SD and NY meeting with potential collaborators 2. Hard NO on leikopheresis clinic holding up MAA with weird caveat3. Still TBD if full or conditional approval 4. Hard NO on back-up manufacturing site holding up MAA. As far as that statement, IDFK maybe the MHRA reviewers might see it as a positive sign that they are holding up production or that NWBO is addressing potential bottlenecks or survival concerns that might might have been a concern at CHM but not part of the actual review.
The way I looked at that statement was that the original MAA was OK w the current existing leukopheresis capacity but NWBO realizes that it's not adequate for, as you say, a rapid ramp.
Market Data 
Markets 
AI
